Abstract: An endo-tracheal catheter for use in an anesthetic procedure comprises a catheter tube to be inserted into the trachea of a patient, the catheter tube having a tubular wall defining an inner lumen for guiding a gaseous flow, and a connection piece which defines a chamber in fluid connection with the catheter tube and comprising a port for connecting a detection device to the endo-tracheal catheter for detecting at least one substance in the gaseous flow flowing through the catheter tube. An insert tube is received in the inner lumen of the catheter tube for guiding the gaseous flow through the catheter tube and/or a coating covers the tubular wall at a side facing the inner lumen for guiding the gaseous flow through the catheter tube.

Abstract: The invention relates to lyophilized products and reconstituted emulsions for parenteral application, which comprise all the 13 essential vitamins (A, D, E, K1, C, B1, B2, B3, B5, B6, B7, B9, and B12) in a single container, as well as to methods for preparing them.

Abstract: The present invention relates to a method for purifying anti-IL-6 receptor antibodies from a sample comprising said antibodies and impurities, through the use of a three-chromatographic columns procedure, including a chromatography on Fluorapatite-containing resin. The invention is also concerned with pharmaceutical compositions comprising the purified antibodies obtainable by the process of the invention.

Abstract: The present invention relates to a method for purifying adalimumab or a biosimilar thereof from a sample comprising adalimumab or a biosimilar thereof and impurities, through the use of hydroxyapatite resin in a Bind/Elute (B/E) mode under conditions such that the adalimumab or a biosimilar thereof binds to the resin and at least a portion of the impurities remain unbound. The invention is also concerned with a pharmaceutical compositions=of the purified adalimumab or a biosimilar thereof, and adalimumab or a biosimilar thereof obtainable by the process of the invention.

Abstract: A control circuitry (11) comprises an adjustable capacitor (C1), and a bias source (111) configured to apply a bias voltage (V2) to said adjustable capacitor (C1) to adjust a capacitance value of the adjustable capacitor (C1). Such a control circuitry may for example be part of a sealing device (1) to seal a medical tubing (2), the sealing device (1) comprising a receptacle (100) to receive said medical tubing (2), the receptacle (100) comprising an electrode arrangement for causing a heat action on the tubing (2).

Abstract: A sealing element is received between a connector and an attachment member. The sealing element includes a foot section received by a recess of the connector, a shoulder engaging an inner surface of the attachment member, and a flange engaging a support surface of the connector. The sealing element also includes a cylindrical body extending from the shoulder to the flange along an insertion direction and, where the cylindrical body deforms to create a flow path through the sealing element, and a sealing head defines an opening that transitions from a closed state to an open state when the cylindrical body deforms.

Abstract: Described herein are wearable devices and methods for medicament delivery. Example devices can include a housing having an underside adapted to be proximate to a skin surface, and a reservoir disposed in the housing, the reservoir configured to be filled with a medicament to be delivered to the patient. The devices can include a cannula disposed within the housing and coupled to the reservoir, in which the cannula configured to protrude from a port defined by the housing to be positioned in the skin surface. The devices can further include a capacitive sensor configured to detect whether the medicament has leaked from the delivery device, in which the capacitive sensor includes a conductor disposed in a portion of the underside of the housing.

Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.

Abstract: The invention relates to a valve unit for a system for producing a parenteral nutrition, in which a three-way valve is used for respectively two connections to a source container. The valve unit is a component which is mounted on the system and can be removed again following use. The valve unit is in particular provided as a replaceable disposable component.

Abstract: The invention relates to an installation for producing a medical preparation, in particular for producing a preparation for parenteral nutrition. The installation comprises a pump with which liquids can be transferred from a plurality of source containers into a target container. The installation has a modular construction and comprises a weighing module and a main module with the pump. According to a further aspect of the invention, the pump is arranged at an inclination with respect to a vertical plane. According to a further aspect of the invention, the installation comprises cascaded valve nodes.

Abstract: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidiazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.

Abstract: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.

Abstract: A drug delivery assembly is provided for delivering a medicament to a patient via a fluid flow path. The assembly includes a main body having a body housing with a body interface and a controller. The assembly also includes a cartridge having a cartridge housing with a cartridge interface configured to be removably associated to the body interface. A drug reservoir positioned within the cartridge housing is configured to contain a medicament and includes an outlet. An adhesive pad is associated with a surface of the cartridge housing and is configured to removably attach to a human body surface. The controller is configured to execute a drug delivery routine in which at least a portion of the medicament in the drug reservoir is delivered to a subject via the outlet and the fluid flow path when the main body is coupled to the cartridge.

Abstract: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.

Abstract: The invention relates to a welding tool and a method for pulse welding films of plastic for medical packs formed as bags. The invention generally provides for the film material that has been plastified during welding, and is consequently free-flowing, to be specifically displaced by increasing the sealing surface area. The displaced film material can for instance compensate for dimensional and form tolerances. At the same time, however, the strength of the welded seam region, which adjoins the interior space of the bag, is not reduced.

Abstract: Device for blood container processing having a data storage reader unit 20 being adapted to read an blood donator identifier from a data storage of a blood container, and a data processing unit 50 being adapted to request for blood donator related information from an data base 163 based on the read blood donator identifier to allow a correct processing of all relevant information with respect to a blood donator and a blood recipient, to match the blood correctly and to avoid any serious injuries on the blood recipient side.

Abstract: A drug delivery assembly includes a main body and a cartridge. The body includes a housing, an adhesive pad, and a body interface that detachably associates with a cartridge interface of the cartridge. A fluid flow path extends through the body housing, between a first end configured to open a seal of the cartridge and a second end configured to enter a human body. The cartridge contains a drug reservoir having an outlet and holding a medicament. The seal prevents the medicament from exiting the reservoir and maintains pressure within the reservoir until the seal is opened by the first end of the fluid flow path when the cartridge is coupled to the main body, placing the reservoir into fluid communication with the flow path. A controller actuates a valve within the body to selectively allow and prevent flow through the flow path during an automated drug delivery routine.

Abstract: The invention relates to PUFA, vitamin E, vitamin D and the protein bound amino acids glycine, arginine and tryptophan as active ingredients for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients, wherein an effective amount of said active ingredients is administered in the form of a nutritional composition comprising a) a lipid component providing 40-50 EN % based on the total energy of the nutritional composition, wherein 12-16 EN % based on the total energy of the nutritional composition is provided by PUFA, b) 4.0-8.0 mg/100 mL alpha-TE vitamin E, c) 5.0-12.0 ?g/100 mL vitamin D, d) 2.5-4.5 g/100 mL glycine, e) 0.5-1.5 g/100 mL arginine, and f) at least 0.02 g/100 mL tryptophan.

Abstract: An on-body drug delivery device having a housing and a cartridge removably attachable to the housing. The cartridge comprises: a drug chamber, a piston received in the drug chamber movable from a first, initial position to a second position, an actuation device for moving the piston from the first position to the second position, and at least one breakable sterility sensor circuit formed by attachment of the cartridge to the housing, the circuit being closed when the cartridge is properly attached to the housing and broken if the cartridge is not properly attached to the housing or removed from the housing after being attached thereto, and/or the circuit being broken if the piston is not in the initial position when the cartridge is first attached to the housing.

Abstract: A prefilled syringe and a method of filling a syringe with a pegfilgrastim solution to provide a target extracted volume of pegfilgrastim solution from the syringe are described. A method includes selecting the target extracted volume of pegfilgrastim solution, determining an estimated drug transfer loss, determining an estimated syringe dead volume, filling the syringe with a volume of pegfilgrastim solution comprising at least the target extracted volume plus the estimated drug transfer loss plus the estimated syringe dead volume.